Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News
Price
$34.10
Movement
0.03 (+0.09%)
as at 10 Jun - Closed (20 mins delayed)
52 Week Range
$26.70 - $35.76
1 Year Return
+21.48%
Fisher & Paykel Healthcare Corp Ltd Chart and Price Data
2025
2025
2025
2025
$25
$30
$35
$40
$25
$30
$35
$40
$25
$30
$35
$40
$25
$30
$35
$40
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$19.99 billion
P/E Ratio
57.43
Dividend Yield
1.12%
Shares Outstanding
586.26 million
Earnings per share
0.639
Dividend per share
0.39
Year To Date Return
-2.52%
Earnings Yield
1.74%
Franking
-
Share Price
$34.10
Day Change
0.03 (+0.09%)
52 Week Range
$26.70 - $35.76
Yesterday's Close
$34.07
Today's Open
$33.88
Days Range
$33.70 - $34.26
Volume
387,267
Avg. Volume (1 month)
431,068
Turnover
$13,167,004
as at 10 Jun - Closed
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News
Healthcare Shares
The ResMed (ASX:RMD) share price is up 25% in 2020
Share Fallers
Why Fisher & Paykel Healthcare, Mesoblast, Splitit, & WiseTech are dropping lower
Share Market News
Why healthcare, tech and consumer staples shares underperformed the ASX 200 in November
Share Gainers
2 ASX 200 healthcare shares that outperformed in November
ASX Shares
ASX 200 drops on Friday
Mergers & Acquisitions
Is it too late to buy the surging Bega (ASX:BGA) share price?
Share Gainers
Why Air NZ, Bega Cheese, Fisher & Paykel Healthcare, & Galaxy are pushing higher
Share Market News
Top brokers name 3 ASX shares to sell today
ASX Shares
Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher
Share Market News
ASX 200 up 0.8%: Fisher & Paykel Healthcare impresses, Harvey Norman's profits surge
Share Market News
Fisher & Paykel (ASX:FPH) share price on watch following half-year results
Share Market News
5 things to watch on the ASX 200 on Wednesday
Frequently Asked Questions
-
Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.
-
Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.
-
Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.
-
Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.
-
Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 05 Dec 2024 | $0.1678 | 0.00% | Interim | 18 Dec 2024 |
| 26 Jun 2024 | $0.2137 | 0.00% | Final | 10 Jul 2024 |
| 05 Dec 2023 | $0.0318 | 0.00% | Supplemental | 18 Dec 2023 |
| 05 Dec 2023 | $0.1800 | 0.00% | Interim | 18 Dec 2023 |
| 26 Jun 2023 | $0.0406 | 0.00% | Supplemental | 07 Jul 2023 |
| 26 Jun 2023 | $0.2117 | 0.00% | Interim | 07 Jul 2023 |
| 08 Dec 2022 | $0.0309 | 0.00% | Supplemental | 21 Dec 2022 |
| 08 Dec 2022 | $0.1645 | 0.00% | Interim | 21 Dec 2022 |
| 22 Jun 2022 | $0.0397 | 0.00% | Supplemental | 06 Jul 2022 |
| 22 Jun 2022 | $0.2029 | 0.00% | Final | 06 Jul 2022 |
| 02 Dec 2021 | $0.0300 | 0.00% | Supplemental | 15 Dec 2021 |
| 02 Dec 2021 | $0.1784 | 0.00% | Interim | 15 Dec 2021 |
| 24 Jun 2021 | $0.0388 | 0.00% | Supplemental | 07 Jul 2021 |
| 24 Jun 2021 | $0.2046 | 0.00% | Final | 07 Jul 2021 |
| 03 Dec 2020 | $0.0282 | 0.00% | Supplemental | 16 Dec 2020 |
| 03 Dec 2020 | $0.1510 | 0.00% | Interim | 16 Dec 2020 |
| 06 Jul 2020 | $0.0274 | 0.00% | Supplemental | 17 Jul 2020 |
| 06 Jul 2020 | $0.1463 | 0.00% | Final | 17 Jul 2020 |
| 06 Dec 2019 | $0.0212 | 0.00% | Supplemental | 19 Dec 2019 |
| 06 Dec 2019 | $0.1148 | 0.00% | Interim | 19 Dec 2019 |
| 13 Jun 2019 | $0.1287 | 0.00% | Final | 05 Jul 2019 |
| 07 Dec 2018 | $0.0172 | 0.00% | Supplemental | 21 Dec 2018 |
| 07 Dec 2018 | $0.0921 | 0.00% | Interim | 21 Dec 2018 |
| 21 Jun 2018 | $0.0221 | 0.00% | Supplemental | 06 Jul 2018 |
| 21 Jun 2018 | $0.1151 | 0.00% | Final | 06 Jul 2018 |
| 05 Dec 2017 | $0.0154 | 0.00% | Supplemental | 20 Dec 2017 |
| 05 Dec 2017 | $0.7802 | 0.00% | Interim | 20 Dec 2017 |
| 15 Jun 2017 | $0.0199 | 0.00% | Supplemental | 07 Jul 2017 |
| 15 Jun 2017 | $0.1074 | 0.00% | Final | 07 Jul 2017 |
| 06 Dec 2016 | $0.0789 | 0.00% | Interim | 21 Dec 2016 |
| 16 Jun 2016 | $0.0955 | 0.00% | Final | 08 Jul 2016 |
| 09 Dec 2015 | $0.0629 | 0.00% | Interim | 23 Dec 2015 |
| 17 Jun 2015 | $0.0710 | 0.00% | Final | 10 Jul 2015 |
| 03 Dec 2014 | $0.0537 | 0.00% | Interim | 19 Dec 2014 |
| 18 Jun 2014 | $0.0650 | 0.00% | Final | 04 Jul 2014 |
| 04 Dec 2013 | $0.0491 | 0.00% | Interim | 19 Dec 2013 |
| 19 Jun 2013 | $0.0586 | 0.00% | Final | 05 Jul 2013 |
| 29 Nov 2012 | $0.0426 | 0.00% | Interim | 14 Dec 2012 |
| 20 Jun 2012 | $0.0550 | 0.00% | Final | 06 Jul 2012 |
| 30 Nov 2011 | $0.0413 | 0.00% | Interim | 16 Dec 2011 |
| 22 Jun 2011 | $0.0534 | 0.00% | Final | 08 Jul 2011 |
| 01 Dec 2010 | $0.0418 | 0.00% | Interim | 17 Dec 2010 |
| 28 Jun 2010 | $0.0000 | 0.00% | Final | 09 Jul 2010 |
| 10 Dec 2009 | $0.0301 | 0.00% | Interim | 18 Dec 2009 |
| 22 Jun 2009 | $0.0476 | 0.00% | Final | 06 Jul 2009 |
| 04 Dec 2008 | $0.0095 | 0.00% | Supplemental | 12 Dec 2008 |
| 04 Dec 2008 | $0.0000 | 0.00% | Interim | 12 Dec 2008 |
| 19 Jun 2008 | $0.0062 | 0.00% | Supplemental | 27 Jun 2008 |
| 19 Jun 2008 | $0.0700 | 0.00% | Final | 27 Jun 2008 |
| 06 Dec 2007 | $0.0095 | 0.00% | Supplemental | 14 Dec 2007 |
| 06 Dec 2007 | $0.0473 | 0.00% | Interim | 14 Dec 2007 |
| 21 Jun 2007 | $0.0124 | 0.00% | Supplemental | 29 Jun 2007 |
| 21 Jun 2007 | $0.0700 | 0.00% | Final | 29 Jun 2007 |
| 23 Nov 2006 | $0.0095 | 0.00% | Supplemental | 01 Dec 2006 |
| 23 Nov 2006 | $0.0540 | 0.00% | Interim | 01 Dec 2006 |
| 19 Jun 2006 | $0.0124 | 0.00% | Supplemental | 28 Jun 2006 |
| 19 Jun 2006 | $0.0700 | 0.00% | Final | 28 Jun 2006 |
| 02 Dec 2005 | $0.0095 | 0.00% | Supplemental | 09 Dec 2005 |
| 02 Dec 2005 | $0.0540 | 0.00% | Interim | 09 Dec 2005 |
| 08 Jun 2005 | $0.0102 | 0.00% | Supplemental | 17 Jun 2005 |
| 08 Jun 2005 | $0.0580 | 0.00% | Final | 17 Jun 2005 |
| 24 Nov 2004 | $0.0088 | 0.00% | Supplemental | 03 Dec 2004 |
| 24 Nov 2004 | $0.0500 | 0.00% | Interim | 03 Dec 2004 |
| 14 Jun 2004 | $0.0494 | 0.00% | Supplemental | 18 Jun 2004 |
| 14 Jun 2004 | $0.2800 | 0.00% | Final | 18 Jun 2004 |
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 10th Jun 2025 2025-06-10T07:30:35 | Notification of closing date for Director nominations | YesNo | 7:30am | 1 | 84k |
| 5th Jun 2025 2025-06-05T12:55:28 | Ongoing Disclosure Notice - Ordinary Shares | YesNo | 12:55pm | 2 | 109k |
| 28th May 2025 2025-05-28T10:06:57 | Dividend/Distribution - FPH | YesNo | 10:06am | 4 | 15k |
| 28th May 2025 2025-05-28T07:31:21 | Preliminary Final Report | YesNo | 7:31am | 238 | 17M |
| 30th Apr 2025 2025-04-30T09:13:43 | FPH announces 2025 Investor Event in Melbourne | YesNo | 9:13am | 1 | 84k |
| 14th Apr 2025 2025-04-14T15:27:25 | Ceasing to be a substantial holder | YesNo | 3:27pm | 5 | 196k |
| 10th Apr 2025 2025-04-10T07:30:08 | FPH to announce full year results on 28 May 2025 | YesNo | 7:30am | 1 | 85k |
| 9th Apr 2025 2025-04-09T15:47:34 | Change in substantial holding | YesNo | 3:47pm | 16 | 352k |
| 7th Apr 2025 2025-04-07T14:16:01 | Ongoing Disclosure Notices - Employee Share Purchase Scheme | YesNo | 2:16pm | 8 | 293k |
| 7th Apr 2025 2025-04-07T13:59:16 | Application for quotation of securities - FPH | YesNo | 1:59pm | 6 | 17k |
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.
The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.
Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico.
FPH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Jun 2025 | $34.07 | $-0.65 | -1.87% | 399,995 | $34.39 | $34.73 | $33.84 |
| 05 Jun 2025 | $34.72 | $0.32 | 0.93% | 334,564 | $34.51 | $34.72 | $34.26 |
| 04 Jun 2025 | $34.40 | $0.05 | 0.15% | 405,518 | $34.32 | $34.48 | $33.77 |
| 03 Jun 2025 | $34.35 | $-0.49 | -1.41% | 837,019 | $34.50 | $34.83 | $33.76 |
| 02 Jun 2025 | $34.84 | $0.91 | 2.68% | 578,841 | $34.21 | $34.89 | $33.81 |
| 30 May 2025 | $33.93 | $1.70 | 5.27% | 1,071,451 | $32.37 | $34.02 | $32.23 |
| 29 May 2025 | $32.23 | $-0.26 | -0.80% | 524,294 | $32.98 | $33.25 | $32.00 |
| 28 May 2025 | $32.49 | $-1.63 | -4.78% | 790,461 | $33.96 | $34.05 | $32.25 |
| 27 May 2025 | $34.12 | $0.79 | 2.37% | 259,859 | $33.75 | $34.23 | $33.50 |
| 26 May 2025 | $33.33 | $-0.06 | -0.18% | 224,095 | $33.22 | $33.65 | $32.96 |
| 23 May 2025 | $33.39 | $-0.62 | -1.82% | 221,008 | $33.58 | $33.63 | $33.03 |
| 22 May 2025 | $34.01 | $0.17 | 0.50% | 256,347 | $33.61 | $34.01 | $33.26 |
| 21 May 2025 | $33.84 | $1.01 | 3.08% | 235,428 | $33.35 | $33.99 | $33.20 |
| 20 May 2025 | $32.83 | $-0.66 | -1.97% | 521,098 | $32.98 | $33.32 | $31.96 |
| 19 May 2025 | $33.49 | $-0.60 | -1.76% | 332,871 | $34.09 | $34.09 | $32.95 |
| 16 May 2025 | $34.09 | $-0.10 | -0.29% | 342,690 | $34.36 | $34.36 | $33.90 |
| 15 May 2025 | $34.19 | $1.03 | 3.11% | 422,697 | $33.33 | $34.37 | $33.12 |
| 14 May 2025 | $33.16 | $0.07 | 0.21% | 317,777 | $33.13 | $33.48 | $32.97 |
| 13 May 2025 | $33.09 | $0.56 | 1.72% | 298,907 | $33.18 | $33.38 | $32.88 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Feb 2025 | Graham McLean | Buy | 1,000 | $32,300 |
On-market trade.
|
| 12 Sep 2024 | Graham McLean | Buy | 800 | $27,932 |
As advised by the company. Purchase of Ordinary Shares, As per announcement on 17-09-2024
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from 2001 to 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mike is a director of Cochlear Limited, Tait International Limited and the Medical Research Commercialisation Fund. Sir Michael was named a Knight Companion of the New Zealand Order of Merit in June 2021. Bachelor of Engineering (Hons) COMMITTEE RESPONSIBILITIES: Chair, Quality, Safety & Regulatory Committee Member, People & Remuneration Committee
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon spent 15 years as Senior Vice President, Products & Technology, and six years as General Manager, Research & Development. During his 42-year tenure with Fisher & Paykel Healthcare, he has held engineering positions overseeing the development of range of products as well the development of manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive DirectorNon-Executive Chairman | Nov 2018 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and a former director of The Board of Tax, South Eastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is member of Risk Committee, People Committee and Quality, Safety & Regulatory Committee.
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Oct 2021 |
Dr McIntyre is a director of The University of Sydney, Studiosity, Nanosonics and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia. She is Chair of People Committee and member of Risk Committee.
|
| Mr Andrew Mark Cross | Non-Executive Director | Oct 2024 |
Mr Cross chairs the board of Chorus and is a director of Xero. He is a board member of Accident Compensation Corporation (ACC) and chair of the ACC Investment Committee. He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property. Mark previously held executive investment banking positions with Deutsche Bank and Lloyds Corporate Finance/ Southpac Corporation, where he was an advisor to companies across a range of sectors. He is Chair of Risk Committee.
|
| Ms Philippa (Pip) Mary Greenwood | Non-Executive Director | Jun 2017 |
Ms Greenwood is chair of both Westpac New Zealand Limited and The a2 Milk Company Limited. She was previously a director of Vulcan Steel and Spark New Zealand and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. Pip was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's board chair. She is member of Risk Committee and People Committee.
|
| Mr Graham McLean | Non-Executive Director | Oct 2023 |
Mr McLean is chair of both CleanSpace Technology and Universal Biosensors. He previously spent 16 years as an executive at leading medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is member of Risk Committee.
|
| Dr Cather Simpson | Non-Executive Director | Jun 2022 |
Dr Simpson is a professor of physics and chemical sciences at the University of Auckland, CEO of Orbis Diagnostics and a partner at Pacific Channel, with experience in lasers and photonics. She is Vice President of the International Society for Optics and Photonics (SPIE) and a member of the Academy Executive Committee of the Royal Society Te Aparangi. Cather is a co founder of three hard-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She founded and directed the Photon Factory at the University of Auckland in 2010. She is member of Quality, Safety & Regulatory Committee.
|
| Ms Raelene Leonard | Company Secretary |
-
|
|
| Lyndal York | Chief Financial Officer |
-
|
|
| Andy Niccol | Chief Operating Officer |
-
|
|
| Raelene Leonard | Company Secretary |
-
|
|
| Desh Edirisuriya | General Manager New Zealand Operations |
-
|
|
| Marcus Driller | Vice President Corporate |
-
|
|
| Nicola Talbot | Vice President Human Resources |
-
|
|
| Nicholas Fourie | Vice President Information & Communication Technology |
-
|
|
| Jonti Rhodes | Vice President Network Design Facilities Infrastructure & Sustainability |
-
|
|
| Dr Andrew Somervell | Vice President Products & Technology |
-
|
|
| Brian Schultz | Vice President Quality Safety & Regulatory Affairs |
-
|
|
| Justin Callahan | Vice President Sales & Marketing |
-
|
|
| Winston Fong | Vice President Surgical Technologies |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Nominees (New Zealand) Limited R601127393 | 72,851,413 | 12.43% |
| JPMorgan Nominees Australia Pty Limited | 57,561,758 | 9.82% |
| HSBC Custody Nominees (Australia) Limited | 56,987,614 | 9.72% |
| HSBC Nominees (New Zealand) Limited R601127385 | 49,522,756 | 8.45% |
| Citicorp Nominees Pty Limited | 45,014,138 | 7.68% |
| JPMorgan Chase Bank | 38,164,940 | 6.51% |
| BNP Paribas Nominees NZ Limited R601338998 | 34,567,359 | 5.95% |
| Citibank Nominees (NZ) Ltd | 26,303,930 | 4.49% |
| Custodial Services Limited | 18,854,845 | 3.22% |
| Tea Custodians Limited | 17,923,982 | 3.06% |
| New Zealand Superannuation Fund Nominees Limited | 14,683,602 | 2.51% |
| Premier Nominees Limited | 7,842,613 | 1.34% |
| Accident Compensation Corporation | 7,828,198 | 1.34% |
| New Zealand Permanent Trustees Limited | 6,561,373 | 1.12% |
| Public Trust | 6,119,187 | 1.04% |
| New Zealand Depository Nominee | 5,708,620 | 0.97% |
| FNZ Custodians Limited | 5,446,374 | 0.93% |
| JBWere (NZ) Nominees Limited | 5,233,917 | 0.89% |
| National Nominees Limited | 4,773,913 | 0.81% |
| BNP Paribas Nominees NZ Limited R601339005 | 4,582,882 | 0.78% |